SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

Cancer Research

Volumn 64, Issue 21, 2004, Pages 7954-7961

  Uhl, Martin ^a   Aulwurm, Steffen ^a   Wischhusen, Jörg ^a   Weiler, Markus ^a   Ma, Jing Ying ^b   Almirez, Ramona ^b   Mangadu, Ruban ^b   Liu, Yu Wang ^b   Platten, Michael ^a   Herrlinger, Ulrich ^a   Murphy, Alison ^b   Wong, Darren H ^b   Wick, Wolfgang ^a   Higgins, Linda S ^b   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD8 ANTIGEN; GAMMA INTERFERON; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; SD 208; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN; CANCER INVASION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; GLIOBLASTOMA; GLIOMA CELL; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN; SUPERNATANT; T LYMPHOCYTE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 7444226411     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1013     Document Type: Article

References (23)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
2. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12:370-4.
3. Fontana A, Hengartner H, de Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 1984;132:1837-44.
4. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 1982;129:2413-9.
5. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995;37:1160-6; discussion 1166-7.
6. Wischhusen J, Jung G, Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002;62:2592-9.
7. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002;168:4772-80.
8. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995;21:128-51.
9. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909-14.
10. Stander M, Naumann U, Dumitrescu L, et al. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 1998;5:1187-94.
11. Leitlein J, Aulwurm S, Waltereit R, et al. Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 2001;166:7238-43.
12. Platten M, Wild-Bode C, Wick W, et al. N-[3,4-Dimethoxycinnamoyl]- anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 2001;93:53-61.
13. Wick W, Grimmel C, Wild-Bode C, et al. Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 2001;21:3360-8.
14. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65:744-52.
15. Valiante NM, Rengaraju M, Trinchieri G. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992;145:187-98.
16. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-14.
17. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998;1:611-7.
18. Tamaki M, McDonald W, Amberger VR, Moore E, Del Maestro RF. Implantation of C6 astrocytoma spheroid into collagen type I gels: invasive, proliferative, and enzymatic characterizations. J Neurosurg 1997;87:602-9.
19. Serano RD, Pegram CN, Bigner DD. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol (Berl) 1980;51:53-64.
20. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Investig 2002;109:1607-15.
21. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002;2:46-53.
22. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002;3:753-66.
23. Ashley DM, Kong FM, Bigner DD, Hale LP. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998;58:302-9.